Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1836-1842

  Sun, L M ^a   Chen, H J ^b   Liang, J A ^b,c   Li, T C ^d,e   Kao, C H ^b,c  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

breast cancer; cohort study; diabetes; population based; tamoxifen

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; ANTIESTROGEN;

ADULT; AGE; ASIAN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DIABETOGENESIS; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MONOTHERAPY; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; REVIEW; SENESCENCE; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; DIABETES MELLITUS; EPIDEMIOLOGY; FOLLOW UP; MIDDLE AGED; PROGNOSIS; PUBLIC HEALTH; RISK FACTOR; TAIWAN; YOUNG ADULT;

ADULT; BREAST NEOPLASMS; COHORT STUDIES; DIABETES MELLITUS; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TAIWAN; TAMOXIFEN; YOUNG ADULT;

EID: 84908529903     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.488     Document Type: Review

References (41)

1. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-Analysis. J Natl Cancer Inst 103: 1299-1309.
2. Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA. Hereditary Breast Cancer Clinical Study Group (2011) Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117: 1812-1818.
3. Bryzgalova G, Gao H, Ahren B, Zierath JR, Galuska D, Steiler TL, Dahlman-Wright K, Nilsson S, Gustafsson JA, Efendic S, Khan A (2006) Evidence that oestrogen receptor-Alpha plays an important role in the regulation of glucose homeostasis in mice: Insulin sensitivity in the liver. Diabetologia 49: 588-597.
4. Cancer Statistics Annual Report (2014) Taiwan Cancer Registry. [Online]. Available at http://tcr.cph.ntu.edu.tw/main.php?Page=N2. Accessed 27 August 2014.
5. Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD (2012) The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control 23: 1193-1203.
6. Department of Health, Taiwan (2012) Mortality statistics of Taiwan in 2012.
7. Department of Health, Executive Yuan, Taiwan. [Online]. Available at http://health99.hpa.gov.tw/Hot-News/h-NewsDetailN.aspx?TopIcNo= 6798. Accessed 11 April 2014.
8. Elisaf MS, Nakou K, Liamis G, Pavlidis NA (2000) Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 11: 1067-1069.
9. Fagan DH, Uselman RR, Sachdev D, Yee D (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: Implications for breast cancer treatment. Cancer Res 72: 3372-3380.
10. Gao CM, Ding JH, Li SP, Liu YT, Qian Y, Chang J, Tang JH, Tajima K (2013) Active and passive smoking, and alcohol drinking and breast cancer risk in Chinese women. Asian Pac J Cancer Prev 14: 993-996.
11. Godsland IF (2005) Oestrogens and insulin secretion. Diabetologia 48: 2213-2220.
12. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2005) Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569-1583.
13. Hardefeldt PJ, Edirimanne S, Eslick GD (2012) Diabetes increases the risk of breast cancer: A meta-Analysis. Endocr Relat Cancer 19: 793-803.
14. Ho GH, Ji CY, Phang BH, Lee KO, Soo KC, Ng EH (1998) Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: A prospective paired cohort study. Ann Surg Oncol 5: 361-367.
15. Hu FB (2011) Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 34: 1249-1257.
16. Huang Q, Wang TH, Lu WS, Mu PW, Yang YF, Liang WW, Li CX, Lin GP (2006) Estrogen receptor alpha gene polymorphism associated with type 2 diabetes mellitus and the serum lipid concentration in Chinese women in Guangzhou. Chin Med J (Engl) 119: 1794-1801.
17. Kim CH, Kim HK, Bae SJ, Kim EH, Park JY (2012) Independent impact of body mass index and metabolic syndrome on the risk of type 2 diabetes in Koreans. Metab Syndr Relat Disord 10: 321-325.
18. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B (2011) Overweight, obesity, diabetes, and risk of breast cancer: Interlocking pieces of the puzzle. Oncologist 16: 726-729.
19. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: A meta-Analysis. Int J Cancer 121: 856-862.
20. Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai MJ, Mauvais-Jarvis F (2006) Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 103: 9232-9237.
21. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K (2008) Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-Aged Swedish men. Diabetologia 51: 1135-1145.
22. Ligibel JA, Strickler HD (2013) Obesity and its impact on breast cancer: Tumor incidence, recurrence, survival, and possible interventions. Am Soc Clin Oncol Educ Book. pp 52-59.
23. Lipscombe LL, Fischer HD, Yun L, Gruneir A, Austin P, Paszat L, Anderson GM, Rochon PA (2012) Association between tamoxifen treatment and diabetes: A population-based study. Cancer 118: 2615-2622.
24. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98: 303-309.
25. Lipscombe LL, Chan WW, Yun L, Austin PC, Anderson GM, Rochon PA (2013) Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 56: 476-483.
26. Liu S, Mauvais-Jarvis F (2009) Rapid, nongenomic estrogen actions protect pancreatic islet survival. Islets 1: 273-275.
27. Lundholm L, Bryzgalova G, Gao H, Portwood N, Falt S, Berndt KD, Dicker A, Galuska D, Zierath JR, Gustafsson JA, Efendic S, Dahlman-Wright K, Khan A (2008) The estrogen receptor {alpha}-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms. J Endocrinol 199: 275-286.
28. MacGregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196.
29. McCarthy NJ (2004) Care of the breast cancer survivor: Increased survival rates present a new set of challenges. Postgrad Med 116: 39-4042, 45-46.
30. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618.
31. Petersson U, Ostgren CJ, Brudin L, Brismar K, Nilsson PM (2009) Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): The Soderakra Cardiovascular Risk Factor Study. Diabetes Metab 35: 198-205.
32. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25: 4772-4778.
33. Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: A review of the evidence. J Clin Oncol 20: 3302-3316.
34. Rondini EA, Harvey AE, Steibel JP, Hursting SD, Fenton JI (2011) Energy balance modulates colon tumor growth: Interactive roles of insulin and estrogen. Mol Carcinog 50: 370-382.
35. Sakhri J, Ben Salem C, Harbi H, Fathallah N, Ltaief R (2010) Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with positive rechallenge. JOP 11: 382-384.
36. Tiano JP, Mauvais-Jarvis F (2012) Importance of oestrogen receptors to preserve functional b-cell mass in diabetes. Nat Rev Endocrinol 8: 342-351.
37. Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivor: Prevalence, pattern, and health consequence. Obes Rev 12: 282-294.
38. Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Lindman H, Bergkvist L, Lambe M (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: A populationbased study. Breast Cancer Res Treat 133: 367-373.
39. Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A, Stebbing J, Lenz HJ (2014) Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. Pharmacogenomics J 14: 28-34.
40. Yang LH, Tseng HS, Lin C, Chen LS, Chen ST, Kuo SJ, Chen DR (2012) Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer 15: 288-295.
41. Yeh WL, Lin HY, Wu HM, Chen DR (2014) Combination treatment of tamoxifen with risperidone in breast cancer. PLoS One 9: E98805.